Here, we utilised CD47 × PD‐L1 BisAb that has been engineered with reduced affinity towards CD47 to negate erythrocyte binding, while retaining engagement with PD‐L1‐expressing cells in the tumor.16 This evidence concerns the gene CD47 and neoplasm.